Abstract:Ketamine as a glutamate receptor antagonist has a rapid, potent, and long-lasting antidepressant effect, but its specific mechanism is still not fully understood. Depression is associated with elevated levels of glutamate and astrocyte loss in the brain; the exploration of the relationships between ketamine's antidepressant effect and astrocytes has drawn great attention. Astrocytes and aquaporin 4 (AQP4) are essential components of the glymphatic system, which is a brain-wide perivascular pathway to help transport nutrients to the parenchyma and remove metabolic wastes. In this study, we investigated pyroptosis-associated protein Nlrp3/Caspase-1/Gsdmd-N expression in the hippocampus of mice and the toxic effect of high levels of glutamate on primary astrocytes. On this basis, the protective mechanism of ketamine is explored. A single administration of ketamine (10 mg/kg) remarkably relieved anxious and depressive behaviors in the sucrose preference test, elevated plus maze test, and forced swim test. Meanwhile, ketamine reduced the level of hippocampus Nlrp3 and the expression of its downstream molecules in chronic unpredictable mild stress (CUMS) mice model by western blot and reduced the colocalization of Gfap and Gsdmd by nearly 25% via immunofluorescent staining. Ketamine also increased the Gfap-positive cells and AQP4 expression in the hippocampus of the CUMS mice. More important, ketamine increased the distribution of the fluorescent tracer of CUMS mice. Treatment with 128 mM glutamate in cortical and hippocampus astrocytes increased the level of Nlrp3, and Gsdmd-N, and ketamine alleviated high glutamate-induced pyroptosis-associated proteins. In summary, these results suggest that high glutamate-induced astrocyte pyroptosis through the Nlrp3/Caspase-1/Gsdmd-N pathway which was inhibited by ketamine and ketamine can improve the damaged glymphatic function of the CUMS mice. The present study indicates that inhibiting astrocyte pyroptosis and promoting the glymphatic circulation function are a new mechanism of ketamine's antidepressant effect, and astrocyte pyroptosis may be a new target for other antidepressant medicines.

Ketamine activated glutamatergic neurotransmission by GABAergic disinhibition in the medial prefrontal cortex

Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

A role of GABA A receptor α1 subunit in the hippocampus for rapid-acting antidepressant-like effects of ketamine

Higher Glutamatergic Activity in the Medial Prefrontal Cortex in Chronic Ketamine Users

Ketamine potentiates a central glutamatergic presynapse

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine

Rapid and sustained restoration of astrocytic functions by ketamine in depression model mice

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

Effects of Low Doses of Ketamine on Pyramidal Neurons in Rat Prefrontal Cortex.

Dynamic Regulation of Phosphorylation of NMDA Receptor GluN2B Subunit Tyrosine Residues Mediates Ketamine Rapid Antidepressant Effects

A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug

Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions

Ketamine blocks bursting in the lateral habenula to rapidly relieve depression

Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression

Ketamine Improves the Glymphatic Pathway by Reducing the Pyroptosis of Hippocampal Astrocytes in the Chronic Unpredictable Mild Stress Model

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms